Evidence map›Paper›PMID 25082669›Full record

ArticleArchives of toxicology2015

Activation of the aryl hydrocarbon receptor by the widely used Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2).

Katrin Frauenstein, Julia Tigges, Anatoly A Soshilov, Sarah Kado, Nadeshda Raab, Ellen Fritsche, Judith Haendeler, Michael S Denison, Christoph F A Vogel, Thomas Haarmann-Stemmann

Abstract read
In one paragraph

Article in Archives of toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Katrin FrauensteinIUF - Leibniz Research Institute for Environmental Medicine, Auf'm Hennekamp 50, 40225, Düsseldorf, Germany.
Julia Tigges
Anatoly A Soshilov
Sarah Kado
Nadeshda Raab
Ellen Fritsche
Judith Haendeler
Michael S Denison
Christoph F A Vogel
Thomas Haarmann-Stemmann
Leibniz Institute of Environmental Medicine · DEUniversity of California, Davis · USDüsseldorf University Hospital · DE

Funding

RECOMBINANT DETECTION SYSTEMS FOR DIOXIN LIKE CHEMICALSR01ES007685 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI DENISON, MICHAEL STEVEN · 1995 to 2019
$4.7M
NIEHS NIH HHS R01 ES007685NIEHS NIH HHS R01ES07685
6 · The paper itself

Abstract

Small molecular weight protein kinase inhibitors are frequently used tools to unravel the complex network of cellular signal transduction under certain physiological and pathophysiological conditions. 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) is a widely used compound to block the activity of Src family kinases, the major group of non-receptor tyrosine kinases, which trigger multiple cellular signaling pathways. Here, we show that PP2 induces cytochrome P450 1A1 mRNA expression and enzyme activity in a dose-dependent manner in human HepG2 hepatoma cells and NCTC 2544 keratinocytes. By means of reporter gene assays, RNA interference, electrophoretic mobility shift assay, and competitive ligand-binding assay, we further demonstrate that PP2 is a ligand for the aryl hydrocarbon receptor (AHR), an intracellular chemosensor that regulates xenobiotic metabolism, environmental stress responses, and immune functions. Upon ligand-dependent activation, the AHR translocates into the nucleus and dimerizes with the AHR nuclear translocator (ARNT) to modulate the expression of its target genes. In addition, AHR activation is frequently accompanied by an activation of the tyrosine kinase c-Src, resulting in stimulation of cell-surface receptors and downstream signal transduction. As PP2 activates the AHR/ARNT pathway by simultaneously blocking c-Src-mediated alternative signaling routes, this compound may be a suitable tool to study the contribution of the different AHR-dependent signaling pathways to biological processes and adverse outcomes. On the other hand, the unexpected property of PP2 to stimulate AHR/ARNT signaling should be carefully taken into account in future investigations in order to avoid a false interpretation of experimental results and molecular interrelations.

Indexed as

Cytochrome P-450 CYP1A1Dose-Response Relationship, DrugElectrophoretic Mobility Shift AssayGene ExpressionGenes, ReporterHep G2 CellsHumansKeratinocytesLigandsProtein BindingPyrimidinesReceptors, Aryl HydrocarbonRNA InterferenceRNA, Messengersrc-Family KinasesAG 1879CYP1A1 protein, humanCytochrome P-450 CYP1A1LigandsPyrimidinesReceptors, Aryl HydrocarbonRNA, Messengersrc-Family Kinases

Identifiers

PMID25082669
PMCPMC4454626
OpenAlexW1965637208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.